Supernus Pharma (SUPN) Misses Q3 EPS by 94c

Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of ($0.80), $0.94 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $192.1 million versus the consensus estimate of $175.82 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• GTCR Is Said To Be In Talks To Buy Software Maker SPS Commerce - Bloomberg
• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• ZoomInfo MCP Server listed on Cursor Marketplace